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The classical paradigm of tuberculosis (TB) immunity, with a central protective role 
for Th1 responses and IFN-γ-stimulated cellular responses, has been challenged by 
unsatisfactory results of vaccine strategies aimed at enhancing Th1 immunity. Moreover, 
preclinical TB models have shown that increasing IFN-γ responses in the lungs is more 
damaging to the host than to the pathogen. Type 1 interferon signaling and altered Th17 
responses have also been associated with active TB, but their functional roles in TB 
pathogenesis remain to be established. These two host responses have been studied 
in more detail in autoimmune diseases (AID) and show functional interactions that are 
of potential interest in TB immunity. In this review, we first identify the role of type 1 
interferons and Th17 immunity in TB, followed by an overview of interactions between 
these responses observed in systemic AID. We discuss (i) the effects of GM-CSF-
secreting Th17.1 cells and type 1 interferons on CCR2+ monocytes; (ii) convergence of 
IL-17 and type 1 interferon signaling on stimulating B-cell activating factor production 
and the central role of neutrophils in this process; and (iii) synergy between IL-17 and 
type 1 interferons in the generation and function of tertiary lymphoid structures and 
the associated follicular helper T-cell responses. Evaluation of these autoimmune-related 
pathways in TB pathogenesis provides a new perspective on recent developments in 
TB research.
Keywords: Mycobacterium tuberculosis, autoimmune diseases, neutrophils, inflammation, tertiary lymphoid 
structures, antibodies, B-cell-activating factor
1. iNTRODUCTiON
Tuberculosis (TB) has been responsible for an estimated one billion deaths worldwide over the last 
200 years (1), which is more than any other infectious disease caused by a single pathogen. Given its 
global magnitude, it has been hypothesized that TB particularly contributed to the genetic selective 
pressure that predisposes for development of autoimmune diseases (AID) (2). This is supported by 
polymorphism studies of the TNF gene, which show an opposite association between susceptibility 
to TB vs. susceptibility to several AID (3). Additionally, a gender-dependent predisposition to either 
TB or AID exists with a male predominance among TB patients (4) opposed to increased AID 
incidences in women (5). The general concept of an inverse relation between infectious diseases and 
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AID is best described by the hygiene hypothesis, which states that 
diminished exposure to infectious pathogens during childhood 
increases the chances of developing AID and allergies (6, 7). Also, 
epidemiologically, the decline in burden of infectious diseases 
over the last century in industrialized countries is accompanied 
by increasing rates of AID (8).
Despite support for an inverse relation, similarities between 
TB and AID have also been identified. TB is even hypothesized 
to be an infection-induced AID based on the observation that 
diverse clinical autoimmune phenomena frequently occur in TB 
patients (9, 10). Furthermore, up to 32% of patients with active 
TB have elevated autoantibody titers (11, 12). Rational explana-
tions for these findings could be that either TB or AID activate 
common immunological pathways (10), or protective immunity 
in TB increases the chance to develop AID (2). In both scenarios, 
key findings in AID immunology could potentially contribute to 
our understanding of TB pathogenesis.
The current paradigm of the host response to Mtb infection 
is summarized in Figure  1. The indispensable role of IL-12/
IFN-γ-mediated Th1 immunity against Mtb has long been 
recognized (13). However, stimulating Th1 immunity in TB 
can also result in excessive inflammation (see Box  1). More 
recently, the contributions of additional immune pathways 
have been explored, especially the role of type I interferons 
(T1-IFNs), Th17 immunity (14, 15), and unconventional 
T  cell immunity (16–18). Little is known about the potential 
interaction between T1-IFNs and Th17 responses in TB, but 
interesting observations in this regard have been reported for 
multiple AID (19–21). To determine if these findings are rel-
evant for the understanding of TB pathogenesis, we first review 
the separate involvements of T1-IFNs and Th17 responses 
in TB pathogenesis in Sections 2 and 3, respectively. Next, 
their known interactions in AID are discussed in Section  4. 
Finally, in Section 5, the potential relevance of these interacting 
pathways in TB is assessed and integrated into the current 
understanding of TB pathogenesis.
2. T1-iFNs iN TB
Type I interferons comprise a family of 13 IFN-α subtypes, IFN-β, 
IFN-ε, IFN-κ, and IFN-ω, which have the shared ability to bind to 
the IFN-α/β receptor (IFNAR) (37). Other interferons include the 
single type II interferon, interferon-γ, and the type III interferon 
family covering three IFN-λ types.
All nucleated cell types are capable of both producing T1-IFNs 
and responding to them, while type II/III interferons are mostly 
produced by leukocytes (37). The main function of T1-IFNs is 
to “interfere” with intracellular infections. Therefore, T1-IFN 
expression is primarily induced through cytoplasmic pattern 
recognition receptors (PRRs) and endosomal toll-like receptors 
(TLRs), which activate distinct interferon regulatory factors 
(IRFs) that act as transcription factors enabling expression of 
interferon-responsive genes (38). In contrast, extracellular patho-
gens trigger surface-bound TLRs that preferentially induce IL-1β 
and TNF-α through activation of NF-κB.
The role of T1-IFNs in infectious diseases is complex (15, 39–
41). T1-IFNs boost the immune system upon pathogen encounter 
by activating dendritic cells and NK cells and by stimulating both 
B-cell responses and CD4+/CD8+ T-cell responses. However, 
T1-IFNs can also induce anti-inflammatory responses to control 
immune-mediated tissue damage during chronic infections. 
These contradictory effects of T1-IFNs in different situations 
can likely be ascribed to the heterogeneity of the T1-IFNs family, 
downstream activation of different STAT homo/heterodimers 
after binding to IFNAR (38, 42) and to differential priming of 
cells prior to induction of T1-IFN signaling (43).
2.1. T1-iFNs in Human TB
When recombinant or purified T1-IFNs became available as 
therapeutic agents in the 1980s, different applications have been 
established based on their antiviral, immune-stimulating, and 
suppressive effects. These include treatment of viral infections 
(e.g., IFN-α treatment of hepatitis B/C infections), AID [e.g., 
IFN-β treatment for multiple sclerosis (MS)], and various malig-
nancies (44). Based on their well-described immune-stimulating 
effect, the use of T1-IFNs as adjuvant to antibiotic treatment for 
patients with active TB has also been explored (see Table 1). All 
studies found a positive influence of adjuvant T1-IFN therapy 
on clinical outcomes in active TB (45–49). Conversely, IFN-α 
treatment without concomitant antibiotic treatment, e.g., for 
hepatitis C, has been described to cause reactivation of latent TB 
(50–57). While reactivation of latent TB and treatment of active 
TB are two distinct clinical situations, the latter finding suggests 
an unfavorable role for T1-IFNs in TB pathogenesis.
In 2010, an interferon-inducible transcriptional signature was 
reported in circulating leukocytes of TB patients, thus linking 
increased T1-IFN signaling with active disease (58). This find-
ing has been validated in several independent studies (59–62). 
A meta-analysis confirmed statistical significance but found a 
less dominant role for T1-IFN-related genes than expected (63). 
This is ascribed to the involvement of signaling components 
downstream of the T1-IFNs receptor in multiple overlapping 
intracellular pathways. Also, association studies do not neces-
sarily implicate a causally detrimental effect of T1-IFNs in TB 
pathogenesis. In line with this, T1-IFN responses show potential 
as biomarkers or diagnostic tool for risk of active disease, but 
their functional involvement during TB progression in patients 
is not yet understood (62).
2.2. Preclinical Studies in Mice Support a 
Detrimental Role of T1-iFNs during  
Acute TB
A causal relationship between T1-IFN signaling and TB disease 
severity was first suggested in 2001 when IFN-α levels in the 
lungs of Mtb-infected mice were shown to be associated with 
Mtb strain virulence (64). Several approaches have been used 
to verify this relationship between increased T1-IFN signaling 
and unfavorable disease outcome. Blocking the T1-IFN signaling 
pathway through use of IFN-α/β receptor knockout (IFNAR−/−) 
improves survival, but only when applied on the background of 
mouse strains in which acute TB is lethal, such as the A129 strain 
(65). In IFNAR−/− mice with a relatively TB-resistant C57BL/6 
background, survival rates were similar to wild-type mice, but 
FigURe 1 | The phases and cell types involved in the immune response to tuberculosis (TB) in the lungs. (1) Inhaled Mtb-containing aerosols are 
deposited deep into the lung, reaching the alveoli (22). Within the alveoli, Mtb are phagocytosed by alveolar macrophages (Alv. MΦ) or infect alveolar epithelial cells 
prior to ending up in alveolar macrophages (23). Within Alv. MΦ, the bacteria are able to inhibit phagosome–lysosome fusion and replicate until cell lysis ensues, 
which takes approximately 3–5 days (24). (2) After the initial contact, Mtb encounters infiltrating myeloid cells of which inflammatory dendritic cells and PMN are 
most readily infected (13, 25). During these early phases, invariate natural killer (iNK) cells and type 1 innate lymphoid cells (ILC1) produce IFN-γ in response to IL-12 
and stimulate myeloid cells to kill phagocytosed Mtb. In addition, γδ T-cells and ILC3 produce IL-17. There is increasing appreciation for the role of tertiary lymphoid 
structures (TLS) and their associated germinal centers (GC) that arise under influence of IL-17 and facilitate optimal activation of myeloid cells and efficient recall 
responses. During this process, loosely aggregated “innate granulomas” are already formed (26). It should be noted that the roles of ILC1s and ILC3s are based on 
their general function, which has not yet been formally demonstrated in TB (27). (3) Onset of adaptive immunity in Mtb infection is delayed to circa 14 days in mice 
and up to 6 weeks in humans (13, 22). At this point, distinct T-cell subsets and B-cells migrate to the site of infection and execute their different effector functions. 
(4) After onset of adaptive immunity, 90–97% of infected individuals develop sustained infection without clinical symptoms termed “latent TB infection” (LTBI) (13). 
LTBI was initially considered a static phase, but it is now known that this stage is hallmarked by the presence of granulomas in various stages (caseous, non-
caseous, and fibrotic) and an ongoing balance between antimycobacterial activity and regulatory mechanisms to minimize immunopathology (13, 28). Cell 
phenotypes are as present in mouse TB models.
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BOx 1 | The dual faces of iFN-γ in tuberculosis (TB) immunity.
In the current paradigm of a successful host response, lung DCs migrate to the 
draining lymph node after Mtb contact and induce a robust IL-12-mediated 
Th1 response (13). This results in migration of IFN-γ-producing CD4+ T-cells to 
the site of infection. Subsequently, activation of macrophages by IFN-γ results 
in killing of intracellular Mtb, while activated CD8+ T-cells lyse infected host 
cells. Conversely, unsuccessful clearance of infection is due to poor activation 
of adaptive immunity. This can result from insufficient antigen presentation 
(29), or from the action of regulatory factors that interfere with Th1 responses 
such as IL-10 or PDL1-PD1 interaction (13). Paradoxically, the current vaccine 
bacillus Calmette–Guérin (BCG) induces a strong Th1 response but is only 
partially effective in protecting against TB (30). Boosting the Th1-inducing 
potential of BCG by using a modified Ankara virus also has yielded disap-
pointing results (31, 32). Thus, solely stimulating Th1 immunity might not be 
the solution in TB prevention. This is confirmed in a mouse TB study showing 
that increasing IFN-γ production by T-cells in the lungs is detrimental to the 
host due to hyper-inflammation that requires PD-1-mediated suppression to 
limit pathology (33). In line with this, Mtb-infected mice deficient in PD-1, or 
mice in which PD-1 is selectively inhibited, display excessive inflammation 
and disease progression (34, 35). Finally, ex vivo studies in human monocyte-
derived macrophages show that protective effects of IFN-γ are dependent on 
multiple factors including time of contact, concentration, and the magnitude of 
the ensuing microbial challenge (36). Based on these observations, it can be 
concluded that boosting IFN-γ production and Th1 immunity in TB, besides 
potentially enhancing protection, can also result in unbalanced inflammation 
in the lungs that is more harmful to the host than to the pathogen. This 
emphasizes the need for involvement of additional immunological pathways 
for optimal protection.
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mycobacterial loads in the lungs were lower (66–69). One study 
actually observed increased loads in the lungs (70) (Table 2).
In a second approach, Mtb-infected mice were supplemented 
with T1-IFNs after start of infection or treated with the TLR3-
ligand poly-ICLC, which stimulates T1-IFN production and 
signaling (64, 72). Both studies showed increased mortality and 
higher mycobacterial loads in the supplemented groups, which 
were not observed when T1-IFNs or poly-ICLC were adminis-
tered to Mtb-infected IFNAR−/− mice. Finally, in a third approach, 
mice were primed with a T1-IFN-inducing influenza virus prior 
to TB infection, which led to enhanced mycobacterial growth and 
reduced survival (73).
Enigmatically, reduced mycobacterial loads in IFNAR−/− mice 
are primarily observed in the acute phase of infection in which 
T1-IFNs are considered immune stimulating. No differences in 
survival or long-term control of infection were found in C57BL/6 
IFNAR−/− mice compared to wild type. In support of this notion, 
T-cell analyses in several of the abovementioned studies con-
vincingly excluded an effect of increased or decreased T1-IFN 
signaling on the adaptive immune response (68, 69, 72). Notably, 
none of these studies addressed the effect of T1-IFNs as adjunct 
treatment to antibiotics, which was shown to be beneficial in TB 
patients (Table 1).
2.3. Mtb Actively induces T1-iFNs
Multiple studies indicate that Mtb employs both active and pas-
sive mechanisms to induce T1-IFNs (74–76). The mycobacterial 
ESAT-6 secretion system (ESX-1) and its 6  kDa early secre-
tory antigenic target (ESAT-6) are essential in this process, as 
mycobacteria lacking ESX-1 fail to induce T1-IFN production 
(67, 77–81). ESAT-6 can disrupt the phagosomal membrane, 
which allows translocation of mycobacteria and mycobacterial 
products from the phagosome into the cytosol (78, 82).
Mycobacteria actively secrete several T1-IFN-inducing com-
pounds, including double-stranded (ds)DNA and the bacterial 
second messenger cyclic-di-AMP (83). These compounds are 
recognized by different cytosolic PRRs, including cGAS (80), 
IFI-204 (78), AIM2 (84), and possibly NOD2 (77), although data 
on the latter are conflicting (67, 78). Activation of these cytosolic 
PRRs converges to activate “STimulator of INterferon Genes” 
(STING), which subsequently forms a complex with TANK-
binding kinase 1 (79). This STING–TBK1 complex activates 
IRF3, leading to IFN-β production in mice (81) as well as human 
dendritic cells (74). IRF3−/− mice are poor producers of IFN-β and 
more resistant to Mtb infection, which supports a negative role 
for T1-IFNs in TB pathogenesis (78).
However, the overall picture is more complex. IRF3−/− mice are 
more resistant to Mtb infection, but mice deficient in the cytosolic 
PRR cGAS, upstream of IRF3, show diminished control of chronic 
Mtb infection (79). This can be traced back to a concomitant 
reduction in autophagy, which is also dependent on the cGAS-
induced activation of the STING–TBK1 axis, but independent 
of IRF3. In line with this, mice infected with an Mtb strain that 
induces higher amounts of cyclic-di-AMP, thus stimulating both 
IRF3-mediated IFN-β production and STING–TBK1-mediated 
autophagy, show improved survival despite increased IFN-β 
levels (83). Taken together, this suggests that pro-mycobacterial 
effects of stimulating the cytosolic PRR/STING/IRF3/IFN-β axis 
by mycobacteria might be outweighed by the antimycobacterial 
effects of the PRR/STING/autophagy pathway.
Autocrine or paracrine IFN-β-signaling induces IRF7 and 
leads to the production of IFN-α in human dendritic cells 
(74). In line with this, injection of recombinant IFN-β in mice 
induces IFN-α production (85). Alternatively, myeloid cells and 
particularly plasmacytoid dendritic (pDC) cells are capable of 
directly activating IRF7-mediated IFN-α production after recog-
nition of Mtb, particularly by endosomal TLR9 (86). In TB, this 
TLR9-IRF7 pathway is studied to lesser extent than the cytosolic 
PRR–IRF3 axis (87). This is possibly due to the dependence of 
T1-IFN-mediated pathogenic effects in mice on ESX-1, which 
induces IRF3 rather than IRF7 as explained above (67). However, 
IRF7 is recognized as commonly induced transcription factor 
by multiple clinical Mtb strains in alveolar epithelial cells (88). 
Moreover, TLR9−/− mice succumb earlier to high-dose Mtb infec-
tion than wild-type mice, which suggests a role for the TLR9/
IRF7/IFN-α axis in TB as well (89).
2.4. T1-iFNs Drive the influx of  
Mtb-Permissive Myeloid Cells 
during Acute infection
Most studies in mouse TB models found significant functional 
effects of T1-IFNs specifically on CD11b+Gr1int myeloid cell 
populations (68, 69, 72). This population comprises monocyte-
derived Ly6ChighCD11c−CCR2high inflammatory macrophages 
(iM) and Ly6CintCD11c+CCR2int inflammatory dendritic cells 
(iDC), but not CD11b+Gr1high PMN (90). This is an important 
TABLe 1 | effect of type i interferons supplementation in human tuberculosis (TB).
Study design Regimen Outcome Side effects Reference
Open parallel, susceptible Mtb 
strain, HIV (−), N = 20 (2 × 10), 
2 months treated
HRZE vs. HRZE + IFN-α  – Less fever on days 3 and 4 after start treatment in HRZE + IFN-α group
 – Increases in total lymphocytes and HLA DR1+ cells after 2 months only in HRZE + IFN-α group
 – Reduction in HRCT score only in HRZE + IFN-α group
 – Stronger reduction of pro-inflammatory cytokines in BALF after 2 months treatment in HRZE + IFN-α group
No adverse 
effects reported
Giosue et al. 
(45)
Patients treated prior for 3–12 years, 
MDR strain, HIV (+), N = 5, 
12 weeks treated
Anti-TB treatment + IFN-α  – 2/5 complete response
 – 1/5 partial response
 – 2/5 no response
 – Increase of NK (% cytotoxicity) in all patients after 12 weeks
Flu-like symptoms 
in 4/5 patients, 
not needing 
treatment
Palmero et al. 
(46)
Patients treated prior for 6 months, 
MDR strain, HIV (−), N = 7, 9 weeks 
treated
DOT + IFN-α  – Significant drop (p = 0.02) in Mtb loads at the end of a 9-week IFN-α treatment course
 – Significant increase (p = 0.03) in Mtb loads after stop of IFN-α treatment
 – Significant drop in IL-1β, IL-6, TNF-α, and IFN-γ pro-inflammatory cytokines; IL-4 and IL-10 showed 
inconsistent changes
No adverse 
effects reported
Giosue et al. 
(47)
Parallel, patients treated prior for 
6 months with DOT, MDR strain, HIV 
(−), N = 12 (2 × 6), 8 weeks treated
1. DOT
2. DOT + IFN-α
 – After 8 weeks, all five subjects of the case group became sputum smear negative; the control group 
remained smear positive (p = 0.012)
 – Evaluation of smear results after 6 months showed two smear-negative subjects in the case group while all 
controls were smear positive (p = 0.132)
4 subjects mild 
arthralgia and 
myalgia, flu-like 
symptoms in all 
subjects
Mansoori et al. 
(48)
Case report, MDR strain, HIV (−), 
N = 1, 2 months treated
HRZE + IFN-α  – Two months after initiation of therapy, sputum smears became negative, the patient’s clinical and 
radiological findings strikingly improved. During 4-year follow-up, all consecutive sputum cultures remained 
negative
No adverse 
effects reported
Zarogoulidis 
et al. (49)
Green text indicates a host-beneficial effect in TB; BALF, bronchoalveolar lavage fluid; DOT, directly observed therapy (antibiotic TB treatment); HRCT, high-resolution computed tomography; HRZE, isoniazid, rifampicin, pyrazinamide, 
and ethambutol; MDR, multidrug resistant.
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TABLe 2 | interference with T1-iFN signaling in preclinical tuberculosis (TB) studies.
Mouse 
back 
ground
intervention Mtb strain Survival Mtb load Reference
A129 IFN-α/β receptor 
knockout 
(IFNAR−/−)
HN878, W4, CDC1551, 
100–200 CFU, aerosol
Better survival against CDC1551
Trend toward better survival 
against HN878
No data Manca et al. (65)
B6D2/F1 Anti-IFN-α/β 
antibody
HN878, 100–200 CFU, aerosol Better survival against HN878 No differences up to day 100 Manca et al. (65)
B6/129 IFNAR−/− H37Rv, HN878, CSU 93, CSU 
123 50–100 CFU, aerosol
No differences in survival after 
infection with all strains
Lower Mtb loads in lungs after infection 
with all strains up to day 150
Ordway et al. (66)
B6 IFNAR−/− Erdman, 106 CFU, i.v. injection No data No differences in lung until day 20
Lower Mtb loads in spleen at day 10 
and day 20
Stanley et al. (67)
B6 IFNAR−/− H37Rv, 100 CFU, aerosol No differences up to day 70 Lower Mtb loads in lungs at day 18,  
no differences at day 25
Desvignes et al. (68)
129S2 IFNAR−/− H37Rv, 200 CFU, aerosol Improved survival Lower Mtb loads at day 21 Dorhoi et al. (69)
B6 IFNAR−/− H37Rv, 500 CFU, aerosol No differences in survival up to 
day 90
Lower Mtb loads at day 21 Dorhoi et al. (69)
B6.SJL IFNAR−/− H37Rv, 100–150 CFU, aerosol No differences in survival up to 
day 90
No data Mayer-Barber et al. (71)
B6/129 IFNAR−/− Erdman, 100 CFU, aerosol No data Higher Mtb loads in lungs on day 10, 
day 20, and day 40
Equal loads at day 80
Cooper et al. (70)
Green text indicates a host-beneficial effect in TB, while red indicates harmful effects.
i.v., intravenous; CFU, Colony Forming Units.
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distinction, as T1-IFNs actively inhibit PMN influx, as discussed 
in more detail in Section 2.4.3.
Inflammatory macrophages and iDC have been identified as 
major contributors to disease progression in mouse TB models 
(91–93). Several lines of evidence suggest that T1-IFNs regulate 
the influx of these cells and play a role in their functional impair-
ment to resist Mtb. This interference with protective immunity 
is multifaceted and concerns four important interactions, which 
will be reviewed separately: (1) T1-IFNs mediate the influx of iM 
and iDC. (2) T1-IFNs inhibit IL-1β responses by these cells, which 
are essential in the initial host responses to Mtb. (3) Prolonged 
IL-1β signaling can also cause excessive inflammation and thus 
requires regulation during later phases. This can be mediated by 
T1-IFNs but also by IFN-γ through functionally different routes. 
(4) T1-IFNs and IFN-γ show a complex interplay in the activation 
of iM and iDC.
2.4.1. T1-IFNs Mediate the Influx of iM and iDC
Mtb-infected mice treated with the T1-IFN-inducing compound 
poly-ICLC show increased numbers of iM and iDC in the lungs, 
which are 10 times more permissive to Mtb infection than their 
counterparts in PBS-treated mice (72). Others confirmed that 
signaling through IFNAR indeed augments the recruitment of 
Mtb-permissive iM and iDC into the lungs (69). Mechanistically, 
IFNAR-dependent expression of the chemokine CCL2 mediates 
the influx of CCR2+ monocytes that differentiate into iM and 
iDC (72). Both myeloid and parenchymal cells can produce 
CCL2 in response to T1-IFNs, but parenchymal cells appear the 
main source of this chemokine (94–96). Expression of CCL2 is 
reduced in the lungs of IFNAR−/− mice, and the pathogenic effects 
of poly-ICLC treatment are absent in Mtb-infected CCR2−/− mice 
(72). Thus, preclinical TB studies indicate that T1-IFNs stimulate 
the influx of CCR2+ monocytes, but not PMN, to the site of 
infection in a CCR2-dependent way via the induction of CCL2 
in parenchymal cells (74–76).
2.4.2. T1-IFNs Inhibit IL-1β Responses  
during Acute TB
Type I interferons not only stimulate the influx of CCR2+ mono-
cytes but also stimulates their differentiation into Mtb-permissive 
iM and iDC (72, 75, 76). This can be traced back to a cross talk 
between T1-IFNs and IL-1β (71, 90). iM and iDC are the major 
sources of IL-1β in the lungs Mtb-infected mice, and IL-1β plays 
a crucial role in the acute host response to Mtb infection (71, 
90). IL-1β augments TNF-α-stimulated Mtb killing and increases 
prostaglandin E2 (PGE2) production by upregulating cyclooxyge-
nase-2 (COX2/PTGS2) (71, 97, 98). PGE2 is involved in control 
of intracellular Mtb replication but also prevents necrotic host cell 
death (99). In accordance, Ptgs2−/− mice, unable to produce PGE2, 
are more susceptible to Mtb infection than wild type mice, but to 
a lesser degree than IL1−/− mice. Further, information on PGE2 in 
TB is given in Box 2.
Type I interferons inhibit the expression and production of 
IL-1β and simultaneously increase the expression of 5-lipoxyge-
nase (5-LO), which is a competitive enzyme for COX2 in the ara-
chidonic acid metabolism (71, 90, 114, 115). As a result, IFNAR 
BOx 2 | The dual faces of prostaglandin e2 (Pge2) in tuberculosis (TB) 
immunity.
Prostaglandin E2 is generally considered a pro-inflammatory mediator and 
indispensable for the induction of fever, which is a hallmark symptom of active 
TB (100, 101). The anti-inflammatory effects of prostaglandin synthase (COX-) 
inhibitors such as NSAIDs underline this notion. However, high levels of PGE2 
can also exert immunosuppressive effects as they stimulate alternative acti-
vation of macrophages (102), inhibit bactericidal activity (103), and promote 
production of IL-10 (104). Moreover, high PGE2 levels can stimulate the deve-
lopment of myeloid-derived suppressor cells with inhibitory effects on adaptive 
immune cells (104, 105). Finally, PGE2 inhibits IL-12 production by DCs and 
IFN-γ production by T-cells, thereby promoting Th2/Th17 immunity (106, 107).
In the serum and bronchoalveolar lavage fluid of TB patients, PGE2 levels 
were found to be elevated (71, 108, 109), and polymorphisms in the PGE2 
receptor EP2 are associated with TB-susceptibility (110). Experimentally, one 
mouse study showed that low PGE2 levels in the acute phase of infection 
are essential for iNOS-mediated control of Mtb (111). Also, PGE2 plays an 
important role during acute TB since the PGE2-producing enzyme COX2 
competes for arachidonic acid substrate with 5-lipoxygenase, which produ-
ces leukotrienes and lipoxins. Hereby, PGE2 prevents necrotic cell death thus 
benefiting the host (71). Opposed to the protective role of low PGE2 levels 
during acute disease, PGE2 levels are higher during the chronic phase of 
TB, and these concentrations contribute to disease by suppressing IFN-γ, 
TNF-α, and iNOS (111). Notably, the cellular source of PGE2 appears to differ 
between acute and chronic TB. During the acute phase of infection, inflam-
matory myeloid cells are the main source of PGE2, while foamy macrophages 
are strong producers of PGE2 during the chronic phase of disease (112). In 
line with a detrimental effect of high PGE2 levels in the chronic phase, foamy 
macrophages are typically associated with disease progression (113).
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signaling causes a shift from COX2-mediated PGE2 production 
to an increase in the 5-LO products such as lipoxin A4 (LXA4) 
and leukotriene B4 (LTB4), which render cells more susceptible to 
necrotic cell death (71, 116). Pharmacological intervention in this 
process by administrating the 5-LO inhibitor Zileuton to Mtb-
infected mice, improved disease outcomes during acute infection 
to similar extent as observed in IFNAR−/− mice (71). An overview 
on the balance between IL-1β and T1-IFNs is given in Figure 2.
2.4.3. Prolonged IL-1β Signaling Causes PMN-
Mediated Tissue Damage and Is Regulated by Both 
T1-IFNs and IFN-γ
The cross talk between T1-IFNs and IL-1β influences disease out-
come in TB (71). However, this does not fully explain the harmful 
effects of T1-IFNs observed in TB. Most importantly, although 
IL-1β production is essential for protective immunity in the acute 
phase of disease in TB, it requires strict regulation as unchecked 
IL-1β signaling in TB can result in excessive PMN-mediated tissue 
damage (120, 123). Also, as explained in Box 2, IL-1β-mediated 
PGE2 production is protective during acute disease but appears to 
have a detrimental effect during chronic disease. Finally, inflam-
matory mediators associated with continuing infection, e.g., 
GM-CSF, predispose for IL-1β production over T1-IFNs by iM 
and iDC (36, 94, 124–126). This reflects an increasing need over 
time to limit IL-1β-mediated inflammatory responses.
To prevent PMN-mediated inflammation caused by exces-
sive IL-1β signaling, the expression and production of IL-1β is 
inhibited not only by T1-IFNs but also by IFN-γ (90, 120). In 
line with this, both T1-IFNs and IFN-γ can inhibit PMN influx 
(127–131). T1-IFNs and IFN-γ can both reduce pro-IL-1β gene 
expression and increase the expression of soluble antagonists for 
the IL-1 receptor (114, 132).
Despite the abovementioned functional similarities between 
T1-IFNs and IFN-γ in IL-1β inhibition, mechanistic differences 
exist between these IFN types in mediating this effect.
Ex vivo studies in human iM and iDC demonstrate that 
IFN-β inhibits IL-1β production more potently than IFN-γ 
(90, 114). One explanation might be that IFN-γ inhibits IL-10, 
while T1-IFNs induce IL-10, which contributes to the inhibition 
of IL-1β production (90, 114, 115). Additionally, an IL-10-
independent inhibition of IL-1β by T1-IFNs was recently identi-
fied (129). T1-IFNs induce cholesterol 25-hydroxylase, which 
potently reduces IL-1β transcription and broadly represses IL-1-
activating inflammasomes. In contrast, IFN-γ inhibits IL-1β 
by increasing intracellular nitric oxide in an iNOS-dependent 
way (120). This prevents NLRP3 inflammasome activation and 
cleavage of pro-IL-1β into IL-1β. In contrast to the mechanisms 
exerted by T1-IFNs, IFN-γ-induced iNOS not only limits 
IL-1β-mediated inflammation but also markedly enhances the 
bactericidal potential of iM (120). Conversely, T1-IFNs suppress 
iNOS production (90). Based on the stimulation of iNOS by 
IFN-γ and the inhibition of iNOS by T1-IFNs, it appears that 
iDC are more sensitive to T1-IFN signaling and iM to IFN-γ 
when both types of interferon are present. T1-IFN-mediated 
inhibition of iNOS appears to occur primarily in iDC, since iDC 
only expressed iNOS in IFNAR−/− mice during viral infection, 
while iM appear more sensitive to IFN-γ and are the main source 
of iNOS in wild-type mice (131).
When taken together, these data suggest that IL-1β inhibition 
by either T1-IFNs or IFN-γ has strong implications on the bacte-
ricidal potential of iM and iDC. Furthermore, T1-IFNs interfere 
with the induction of iNOS by IFN-γ, particularly in iDC. This 
fits the observation that IFN-γ only inhibits IL-1β production by 
iM but not iDC in mouse TB models (90). Notably, iDC are the 
most readily infected cells in the lungs of Mtb-infected mice (25) 
and are present in larger numbers than iM during Mtb infection 
(72, 133).
2.4.4. The Interplay between T1-IFNs and IFN-γ
During direct contact with Mtb through TLRs, endogenous 
T1-IFN signaling through IRF3 promotes IL-12 production by 
iDC over IL-23 (see also Figure 2; Box 3) (94, 134, 135). This 
early IL-12 signaling is required to induce IFN-γ production by 
innate lymphoid cells (ILC) such as NK cells and possibly ILC1s 
(136, 137). However, exogeneous T1-IFNs or T1-IFN signaling in 
the absence of TLR stimulation can also inhibit IL-12 production 
by iDC (115, 138). This inhibition of IL-12 by T1-IFNs occurs 
particularly through induction of IL-10 (15). T1-IFNs also inhibit 
the responsiveness of iDC to IFN-γ-mediated activation, which 
is required for Mtb killing. This occurs partially by reducing the 
expression level of IFN-γ-receptor on the cell surface, but pri-
marily through induction of an IL-10high regulatory phenotype in 
which antimicrobial pathways by IFN-γ are not readily activated, 
as discussed below (90, 115, 131, 139–141).
Recent findings might explain the mechanism behind this 
paradox where T1-IFNs initially support IL-12-mediated IFN-γ 
production by NK cells but can also induce an IL-10high phenotype 
FigURe 2 | inflammatory responses during acute infection in naïve inflammatory macrophages and dendritic cells. Green text indicates a beneficial host 
effect during Mtb infection and red indicates a detrimental effect. Mtb, Mycobacterium tuberculosis; PRR, pattern recognition receptor; STING, STimulator of 
INterferon Genes; TBK1, tank-binding kinase 1; IRF3, interferon regulatory factor 3; 5-LO, 5-lipoxygenase; COX-2, cyclooxygenase 2; PGE2, prostaglandin E2; EP2, 
prostaglandin E2 receptor 2; ILC3, innate lymphoid cells type 3. 1Jayaraman et al. (97), 2Chen et al. (116), 3Shi et al. (107), 4Di Paolo et al. (98), 5Lockhart et al. (117), 
6Boniface et al. (106), 7El-Behi et al. (118), 8Fremond et al. (119), 9Mishra et al. (120), 10Watson et al. (81), 11Fleetwood et al. (94), 12Mayer-Barber et al. (71), 13Antonelli 
et al. (72), 14Une et al. (121), 15Longhi et al. (122), 16Manca et al. (64), 17Manca et al. (65), and 18Mayer-Barber et al. (90).
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in iDC, which interferes with IL-12 production and prevents 
IFN-γ-mediated activation. It has been observed in different 
mouse models, including Mtb-infected mice, that T1-IFNs can 
only induce an IL-10high regulatory phenotype in monocyte-
derived DCs (iregDC) if these cells have been primed previously 
by IFN-γ (43). IFN-γ-primed DCs that did not receive T1-IFN 
signaling differentiated into iDC that stimulated robust T-cell 
responses. This phenomenon of monocyte priming by IFN-γ has 
been demonstrated to occur in the bone marrow (154). During 
gut infections, local production of IL-12 in mucosa-associated 
lymphoid tissue stimulates bone-marrow-resident NK  cells to 
produce IFN-γ as early as 3 days post infection (154). This results 
in a uniform presence of an IFN-γ-primed signature of Ly6Chigh 
monocytes in the circulation at day 6. Furthermore, IFN-γ indeed 
primed these monocytes toward a regulatory phenotype, as they 
more effectively produced IL-10 in response to bacterial ligands 
(154). We speculate that a similar mechanism of IFN-γ priming 
is likely to be involved in pulmonary infections.
These data suggest interplay between T1-IFNs and IFN-γ as 
proposed in Figure 3. T1-IFNs initially induce IFN-γ responses by 
promoting IL-12 production in naïve cells as shown in Figure 2. 
These IL-12 responses stimulate IFN-γ production by ILC not 
BOx 3 | iL-12 or iL-23 production by dendritic cells?
IL-12 and IL-23 are heterodimeric cytokines composed of a common p40 
subunit, coupled with either a p35 subunit in IL-12 or a p19 subunit in IL-23. 
Both IL-12 and IL-23 are produced in particular by stimulated dendritic cells 
and to lesser degree by macrophages. The preferential production of IL-12 
or IL-23 by these cells is multifactorial. Increased levels of PGE2 support 
IL-23 production over IL-12 (106, 107, 142). Activation of TLR2 and TLR4 
also stimulates IL-23 production over IL-12, especially when NOD2 is simul-
taneously activated (143, 144). On the other hand, TLR9 and TLR3 agonists 
preferentially induce IL-12 (135, 145, 146). Downstream of PRRs, activation of 
IRF 4 and 5 favor induction of IL-23, while IRF 1, 3, and 7 induce IL-12 (135, 
147). In line with this, T1-IFN-mediated IRF3 activation and IFN-γ-mediated 
IRF-1-activation both favor IL-12 production (148, 149).
IL-4 also favors IL-12 production and inhibits IL-23 production, especially 
in combination with IFN-γ or GM-CSF (150, 151). Finally, an important pathway 
that promotes IL-12 over IL-23 is ligation of the co-stimulatory molecule CD40 
by CD40L on activated T-cells or by agonist antibodies (152). Taken together, 
IL-23 is induced in the presence of pathogens and innate signaling in the 
acute phase of infection, while onset of adaptive immunity with increased 
levels of IFN-γ and/or IL-4 shifts the balance toward IL-12 (153).
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only locally but also systemically, which results in IFN-γ priming 
of monocytes in the bone marrow. Once IFN-γ production is 
initiated, T1-IFNs mediate a regulatory function by inducing an 
IL-10high phenotype in IFN-γ-primed iDC. This prevents further 
production of IL-12 by these cells, inhibits their activation by 
IFN-γ, and results in an Mtb-permissive phenotype.
2.5. Summary: The Role of T1-iFNs in TB
Several modest clinical successes have been shown with IFN-α 
supplementation adjunct to antibiotic TB treatment (Table  1). 
However, case reports of TB reactivation under IFN-α treatment 
without concomitant antibiotics have put T1-IFNs in a nega-
tive spotlight (50–57). Furthermore, a T1-IFN transcriptional 
signature in circulating leukocytes is associated with active TB. 
Nevertheless, the functional role of T1-IFNs in TB patients 
remains to be determined (62).
Preclinical studies in mice support a detrimental role for 
T1-IFN in the acute phase of Mtb infection. T1-IFN signaling 
was associated with increased mortality in Mtb-susceptible mouse 
strains and higher Mtb loads in the lungs in most studies (Table 2).
However, it should be noted that most of these preclinical 
studies do not unequivocally support a harmful effect of T1-IFNs 
during the chronic phase of disease based on mortality, Mtb 
loads, or differences in adaptive immunity.
In support of a pathogenic role of T1-IFNs during acute infec-
tion, mycobacteria actively induce T1-IFNs by triggering cyto-
solic PRRs. This leads to IFN-β production in an IRF3-dependent 
way. Subsequently, T1-IFNs mediate the CCL2/CCR2-dependent 
migration of iM and iDC into the lungs (72). In these cells, inter-
ference of T1-IFNs with IL-1β and PGE2 as shown in Figure 2 can 
lead to an altered metabolism of arachidonic acids that leaves cells 
more vulnerable to necrotic cell death (71). However, sustained 
IL-1β signaling itself carries the risk of excessive inflammation in 
TB and not only T1-IFNs but also IFN-γ inhibits IL-1β to prevent 
excessive PMN-mediated inflammation (120). T1-IFNs inhibit 
IL-1β more effectively than IFN-γ but stimulate an IL-10high Mtb-
permissive phenotype (72, 90).
Next to their shared ability to inhibit IL-1β, an interesting 
interplay between T1-IFNs and IFN-γ exists in TB as summarized 
in Figure  3. Two recent findings that are of particular interest 
include the observation that T1-IFNs can only induce an IL-10high 
phenotype in IFN-γ-primed cells (43) and the inductive role of 
T1-IFNs in early IL-12 signaling, which is required for IFN-γ 
priming in the bone marrow (154). Further, research into this 
complex interplay between T1-IFNs and IFN-γ during early host 
responses in TB would be highly interesting given the T1-IFN-
inducing capacities of Mtb and the shaping effect of early T1-IFN 
or IFN-γ signaling on the ensuing immune response.
3. THe Th17 ReSPONSe iN TB
As discussed in the previous paragraph, T1-IFNs induce IL-12 
production by iDC, while IL-1β induces IL-23. Other factors 
also influence production of IL-12 or IL-23 (see Box 3). IL-12 is 
essential for the induction of IFN-γ responses in TB, but IL-1β 
is protective during acute TB despite inducing IL-23 over IL-12. 
Similar to the requirement of IL-12 for Th1 responses, IL-23 is 
essential for establishing Th17 immunity (157–159). Here, we 
review the effect of IL-23 signaling and the Th17 response in TB.
3.1. introduction to the Th17 Response
The Th17 response is distinct from classical cell-mediated Th1 
immunity or B-cell-stimulating Th2 responses and is often asso-
ciated with a potent inflammatory response and tissue damage 
(159). Th17 cells display a high degree of plasticity and their abil-
ity to express signature markers of other T-helper lineages makes 
it difficult to establish their exact role in disease. Four different 
subsets of Th17 cells have been described to date with ranging 
inflammatory potential (160). On one side of the spectrum are 
highly inflammatory and often pathogenic IFN-γ/GM-CSF-
producing Th17.1 cells that result from prolonged IL-1β and 
IL-23 signaling (161). On the other side are IL-10-producing 
Th17  cells, which can even transdifferentiate into regulatory 
T-cells and contribute to resolution of inflammation (162).
Despite the plasticity in cytokine production, IL-17 remains 
the hallmark cytokine of the Th17 response. Next to Th17 cells, 
γδ T-cells and ILC3 can also produce IL-17 in response to IL-23 
and IL-1β (27, 117, 163). IL-17 exerts its effects primarily on 
nearby parenchymal cells and to lesser extent on hematopoietic 
cells, which is distinct from Th1 and Th2 cytokines like IFN-γ and 
IL-4 (159). In parenchymal cells, IL-17 primarily stimulates the 
production of the chemokines that attract PMN (164). However, 
it should be noted that IL-17 alone is a poor inducer of these 
chemokines and that synergistic activation by inflammatory 
ligands such as IL-1β, TNF-α, or GM-CSF markedly increases 
the effects of IL-17 (164, 165).
3.2. The Th17 Response in Human TB 
infection
The exact role of the Th17 response in human TB remains a 
topic of debate (13, 14, 166). Polymorphisms in genes encoding 
IL-17 are associated with susceptibility to pulmonary TB, which 
indicates a role for this cytokine in TB (167–170). However, these 
FigURe 3 | Hypothetical interplay between type i interferons (T1-iFNs) and iFN-γ in monocyte priming and shaping of the immune response in Mtb 
infection. Dashed lines indicate speculations in the context of pulmonary Mtb infection; solid lines indicate shown pathways in human and/or in animal models. (1) 
T1-IFN induces migration of CCR2+ monocytes (iMo) from the bone marrow to the lungs of Mtb-infected mice under influence of CCL2 (72). Locally, these cells 
develop into CD11b+Ly6Chigh inflammatory macrophages (iM) and CD11b+Ly6Cint inflammatory dendritic cells (iDC) (43). (2) As shown in Figure 1, naïve iM and iDC 
can initiate either IL-1β-mediated inflammation or T1-IFN-mediated inflammation. Mtb actively triggers intracellular pattern recognition receptors to induce a 
T1-IFN-mediated response. (3) Additionally, iM and iDC in the naïve situation have differentiated under influence of M-CSF, which makes them more responsive to 
T1-IFN signaling (94). During progression of Mtb infection, GM-CSF levels rise and increase the potential for IL-1β production by iM and iDC (94, 125, 155, 156). (4) 
Similar to the situation in gut infection, we propose that in tuberculosis (TB) IL-12 production in the lungs stimulates IFN-γ production by bone-marrow-resident 
NK cells, which locally primes monocytes (154). IFN-γ priming of monocyte-derived iDC is necessary for T1-IFNs to induce a regulatory (iregDC) phenotype in iDC in 
the lungs (43). (5) Additionally, IFN-γ stimulates monopoiesis over granulopoiesis by granulocyte/macrophage progenitor cells (128). (6) As Mtb infection progresses 
and GM-CSF levels increase, iM and iDC readily produce IL-1β [see also (3)] (124, 155), which can lead to PMN-mediated inflammatory damage in TB (120). (7) 
IL-1β production can be inhibited in response to either IFN-γ or IFN-β through mechanistically distinct pathways that differently affect Mtb killing. (8) Signaling 
through IFN-α/β receptor in IFN-γ-primed iDCs induces IL-10 production (43, 115, 131), inhibits IL-12 production (115), and makes these cells unresponsive to 
activation by IFN-γ (43, 115, 141), which together interfere with protective immunity during acute Mtb infection.
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findings could not be reproduced in different demographic set-
tings (171, 172).
Analyses of Th17 responses in peripheral blood mononuclear 
cells (PBMC) from TB patients do not show uniform results either. 
Direct ex vivo analyses of unstimulated circulating CD4+ T-cells 
show that active TB (ATB) is associated with reduced frequencies 
of circulating Th17 cells compared to latent TB infection (LTBI) 
(173, 174). However, serum IL-17 levels do not differ between 
ATB and LTBI, and IL-17 is undetectable in the bronchoalveolar 
lavage fluid during both stages of disease (174, 175).
Different studies report PBMC stimulation assays with Mtb-
specific antigens showing either increased or reduced Th17 
responses in ATB compared to LTBI (Table  3). These diverse 
findings are similar to those observed in IFN-γ response assays 
(IGRA), in which the levels of IFN-γ often also cannot discrimi-
nate between ATB and LTBI (176, 177). Interestingly, both Th1 
and Th17 cells appear functionally inhibited in ATB patients by a 
PD-1-mediated immunosuppressive state (178–181). In accord, 
reductions in PD-1 expression under TB treatment restored both 
Th1 and Th17 responses (182).
TABLe 3 | iL-17 responses in patients with active TB (ATB) compared to 
latent tuberculosis infection (LTBi).
increased in ATB No difference Reduced in ATB
% of IL-17+CD4+ T-cells
Short 
incubation 
(0–48 h)
Basile et al. (183)a Marin et al. (184, 
185)
Scriba et al. (175); 
Perreau et al. (186)
Long 
incubation 
(72–144 h)
Jurado et al. (187); 
Marin et al. (184)
Cowan et al. (174); 
Marin et al. (185)
Perreau et al. (186); 
Heidarnezhad et al. 
(188)
Ex vivo IL-17 
production
Jurado et al. (187); 
Xu et al. (189)
Sargentini et al. 
(190); Cowan et al. 
(174); Kim et al. 
(191)
Kumar et al. (192); 
Nunnari et al. (193); 
Bandaru et al. (182)
aOnly in MDR-TB.
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Taken together, systemic Th17 responses in TB patients dem-
onstrate similar variability as observed for IGRA studies. Both 
are unable to distinguish ATB from LTBI. How these systemic 
responses relate to local host responses in the lungs has not been 
characterized in TB patients.
3.3. Preclinical Studies in Mice Support a 
Protective Role for iL-23 and iL-17 in TB
Based on mortality and mycobacterial loads, studies in Mtb-
infected mice support a protective role for IL-23 and IL-17 in TB, 
but only during later stages of disease (Table 4).
Interestingly, these late protective effects result from effects 
induced during the initial phase infection (142, 195). This is due 
to the essential roles of IL-23 and IL-17 in the local formation of 
tertiary lymphoid structures (TLS) (199, 200). These structures are 
formed during early infection but can persist for longer periods of 
time and are associated with protective immunity in Mtb-infected 
mice (199, 201) (Table 4; Figure 4). Furthermore, IL-17 and IL-23 
increase the expression of the chemokine CXCL13 (194, 197). 
This chemokine stimulates the influx of TLS-associated CXCR5+ 
follicular helper (Tfh)-cell, which facilitate optimal localization of 
effector T-cell populations within the lung parenchyma, thereby 
promoting efficient T-cell-dependent macrophage activation and 
intracellular Mtb killing (194, 201).
On account of their ability to induce TLS formation, boosting 
IL-23 and IL-17 production is also an interesting strategy for 
vaccine-induced protection against TB. In this regard, IL-17 pro-
duction by Th17 cells during recall responses is indeed dependent 
on IL-23 and could reduce mycobacterial loads in the lungs of 
Mtb-infected mice (210). Th17 cells preferentially migrate to the 
lungs and are better contained in the lungs compared to Th1 cells 
upon adoptive transfer to naïve mice (210, 211). The develop-
mental flexibility of Th17 cells is illustrated in experiments where 
Mtb-antigen-primed Th17 cells have been adoptively transferred 
to naïve mice (210). Initially, these Th17  cells produce IL-17. 
However, upon recall immunity against Mtb, they primarily pro-
duce IFN-γ, with or without IL-17. Paradoxically, the latter switch 
results in a less effective reduction in bacterial loads compared to 
IL-17-producing Th17 cells that are adoptively transferred from 
IFN-γ−/− mice.
This tendency of Th17 cells to produce IFN-γ instead of IL-17 
during recall responses might explain the observation that IL-17 
production during later phases of Mtb infection is dominated by 
γδ T-cells rather than CD4+ cells (117, 198).
When taken together, initial shaping of the local inflamma-
tory environment by IL-17 and IL-23 during acute infection 
stimulates local TLS formation. This facilitates the development 
of more robust Th1 responses by improving contact between 
antigen-presenting cells (APC) and lymphoid cells (Figure  4). 
Furthermore, Th17 cells confer protective immunity during recall 
responses by their enhanced capacity to migrate to the lungs and 
stimulate Tfh responses compared to other CD4+ T-helper cell 
populations.
3.4. The Th17 Response, PMN, and 
inflammatory Damage
IL-17 stimulates granulopoiesis in the bone marrow and increases 
PMN influx to the site of infection by inducing G-CSF, CXCL1, 
CXCL3, and CXCL5 expression by parenchymal cells in mice 
or G-CSF and IL-8 in humans (159). These effects of IL-17 are 
markedly enhanced through synergistic activation by inflamma-
tory mediators such as IL-1β, TNF-α, or GM-CSF (164, 212, 213). 
In this regard, IL-17 is not a strong inducer of inflammation by 
itself, but rather amplifies preexisting inflammation. This IL-17-
mediated “inflammatory boost” can positively shape adaptive 
immunity, but prolonged or repeated antigen exposure can also 
lead to PMN-mediated pathological inflammation (214). Since 
IL-17 signaling is inevitably linked to PMN influx, the role of 
PMN in TB provides an additional perspective on the effects of 
IL-17 signaling in TB.
Review of available literature on the role of PMN in TB yields a 
complex picture with seemingly conflicting effects (14, 166, 215). 
In patients with active TB, PMN are the predominantly infected 
cells in the airways and provide a permissive site for a burst of 
active mycobacterial replication prior to transmission (216). On 
the other hand, PMN from healthy individuals, especially when 
stimulated with TNF-α, show a strong bactericidal effect (217). 
In preclinical TB models, highly susceptible mouse strains such 
as I/St, CBA/J, or DBA/2 show an enhanced influx of apoptosis-
resistant, highly phagocytic neutrophils that negatively affect 
survival compared to more TB-resistant C57BL/6 and BALB/c 
mice (218–220). Moreover, PMN are poor producers of essential 
cytokines such as IL-1α/β and IL-12p40 in the anti-TB response 
(90, 221). These effects in preclinical models primarily suggest 
a negative contribution of PMN to acute disease. However, 
increasing evidence suggests a supportive role for PMN in pro-
tective immunity. PMN can indirectly augment IL-1β-mediated 
inflammatory responses in macrophages after contact with Mtb 
(202, 204, 205). Also, and consistent with Th17 responses, PMN 
play an essential role in generation of protective recall responses 
in Mtb-infected mice (195, 206, 222). Early, but not late PMN 
recruitment is essential for IL-17-mediated long-term control of 
Mtb infection (195). This can be explained by the finding that 
DCs that acquire Mtb through uptake of infected PMN are better 
able to activate T-cells (203, 222). The importance of this mecha-
nism is recently highlighted in Mtb-infected mice, showing that 
TABLe 4 | Th17-related effects in preclinical tuberculosis (TB) studies in mice.
Mice 
(age, 
weeks)
intervention Mtb strain, route Survival Mtb load (vs. wild-type mice) immunological effect Reference
B6 (6–12) IL23
p19−/−
H37Rv (100 CFU), 
aerosol
No data No difference in lungs
1 log higher Mtb load in spleen at 
day 150
No IL-17-producing cells in lungs up 
to day 150
Khader et al. (158)
B6 (6–12) IL23
p19−/−
H37Rv (100 CFU), 
aerosol
No data Day 120 and onward, 0.5–1 log 
higher Mtb load in lungs
Reduced no. of B-cell follicles at day 
200 (Cxcl13 mediated)
Strongly impaired IL-17, IL-22 
production in lungs up to day 250
Khader et al. (194)
B6 (6–12) IL22−/− H37Rv (100 CFU), 
aerosol
No data No effect up to day 200 Suboptimal B-cell follicle development 
(Cxcl13-mediated)
Khader et al. (194)
B6 (6–9) IL-17
RA−/−
H37Rv 
(1.103 CFU), i.t.
Higher 
mortality 
(median 
survival: 18 
vs. 35 weeks)
1.5 log higher Mtb load at week 12 
and week 20 in lungs
Impaired cell recruitment (PMN, 
lymphocytes, Mo/DC)
Increased IL-1β
Decreased TNF-α, IL-6 and IL-10
Freches et al. (195)
B6 (6–12) IL-17
RA−/−
H37Rv (100 CFU), 
aerosol
No data No effect up to day 200 Suboptimal B-cell follicle development 
(Cxcl13-mediated)
Khader et al. (194)
B6 (8–12) IL-17−/− H37Rv 
(1.103 CFU), i.t.
No data 1.5 log higher Mtb load Reduced no. of granulomas at day 28 Okamoto Yoshida 
et al. (196)
B6 (6–8) IL-17−/− HN878 (100 CFU), 
aerosol
No data 1 log higher Mtb load in lungs at 
day 30
0.5 log higher Mtb load in lungs at 
day 60
Infection with HN878 showed robust 
production of IL-1β through TLR2, 
which supported increased IL-17 
production compared to H37Rv and 
CDC1551 
Gopal et al. (197)
B6 (6–8) IL-17−/− H37Rv, CDC1551 
(100 CFU), aerosol
No data No difference at day 30 and day 60 Gopal et al. (197)
B6 (8–12) IL-17−/− H37Rv 
(1.103 CFU), i.t.
Higher 
mortality
1.5 log higher Mtb loads in lungs at 
day 30, 1 log higher Mtb loads at day 
60 and day 120
Impaired granuloma formation, γδ 
T-cells primary source of IL-17
Umemura et al. (198)
Red text indicates a harmful effect to the host; CFU, colony forming units; IL-17RA, IL-17 receptor A; i.t., intratracheal instillation.
12
Mourik et al. Interactions between T1-IFNs and Th17 in TB
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 294
PMN-depletion during vaccination prevented the generation of 
specific Th1 and Th17 responses (206).
A second emerging protective role of PMN is their contribu-
tion to initiating inflammation resolution (223). In mouse TB 
models, PMN are the main producers of IL-10 in the lungs and 
can dampen inflammatory damage (224). In this regulatory role, 
PMN inhibit Th17 responses but do not interfere with IFN-γ-
mediated Th1 immunity due to relative insensitivity of Th1 cells 
to IL-10 (224, 225). Another regulatory effect of PMN concerns 
their apoptosis and subsequent phagocytosis by macrophages in 
the absence of extracellular Mtb. This inhibits IL-23 production 
by these macrophages and induces a regulatory IL-10high M2c 
phenotype under influence of IL-17 and IL-10 (see Figure 4) (226, 
227). IL-17 can further contribute to this process by attenuating 
the anti-apoptotic effect of GM-CSF on PMN and by stimulating 
PMN apoptosis (228, 229).
Taken together, PMN recruitment to the site of infection 
is largely dependent on IL-17, but only in synergy with innate 
inflammatory cytokines such as IL-1β. Locally, these recruited 
PMN contribute to inflammation if pathogens are still present, 
improve dendritic cell function, and contribute to the formation 
of recall responses, or initiate resolution of inflammation in the 
absence of inflammatory or microbial stimuli.
3.5. Summary: The Role of Th17  
immunity in TB
The roles of IL-23 and IL-17 in TB are more subtle than the effects 
of Th1-related cytokines or T1-IFNs. Patient data are mostly lim-
ited to studies in PBMC. These show inconclusive results that are 
possibly confounded by the dynamics and heterogeneity of the 
Th17 response, which can range from highly pro-inflammatory 
IFN-γ/GM-CSF-producing Th17.1 cells to IL-10-producing 
regulatory Th17 cells.
Preclinical mouse TB models provide evidence for a protective 
role of the Th17 cytokines IL-23 and IL-17 in TB. These protec-
tive effects become apparent in the chronic phase of infection 
but result from IL-23/IL-17-mediated effects in the earlier, acute 
phase of infection. This is associated with early protective effects 
of IL-1β, which is a strong inducer of IL-23 and IL-17 (Figure 4). 
Mechanistically, evidence for the protective effects of IL-17 and 
IL-23 primarily points toward their role in the development of 
FigURe 4 | The iL-23/iL-17 axis in acute tuberculosis. (1) When inflammatory dendritic cells (iDC) recognize Mtb through membrane-bound toll-like receptors, 
they can secrete IL-1β, IL-23, and prostaglandin E2 (PGE2) (see Figure 1). This occurs more efficiently if iDC are activated through contact with Mtb-infected PMN, 
which also stimulates their migratory capacity to tertiary lymphoid structures (TLS) and promotes recall immunity (202–206). (2) The combination of IL-1β and IL-23 
induces IL-17 production by γδ T-cells and possibly ILC3 (27, 117). (3) Activation of parenchymal cells by IL-17 in combination with IL-1β or other inflammatory 
mediators ultimately results in PMN influx. (4) PMN contribute to inflammation when stimulated by extracellular Mtb or inflammatory cytokines. (5) Activated PMN 
readily cause tissue damage through production of ROS and proteases; this effect is suppressed by activated iDC in a PGE2-dependent way (112, 207, 208). (6) 
IL-23 and IL-17 stimulate the local production of CXCL13 by stromal cells (194, 199). This promotes TLS formation and follicular helper T-cell migration to the site of 
infection. (7) CD40 ligation in the interaction between (i)DC and CD4+ T-cells is a strong stimulus for IL-12 production over IL-23 (Box 3) and leads to Th1 formation 
and IFN-γ production. (8) IFN-γ inhibits IL-1β production and shifts IL-23 production to IL-12, thus inhibiting IL-17 production and reinforcing the Th1 response (209). 
(9) In the absence of inflammatory stimuli, PMN can produce IL-10 and undergo apoptosis. Phagocytosis of apoptotic PMN induces an IL-10-producing regulatory 
M2c phenotype in macrophages and further contributes to resolution of inflammation.
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TLS during the acute phase of disease, which provides protective 
effects during later stages (199, 230). Additionally, IL-23 and 
IL-17 induce CXCL13 expression that mediates the influx of 
TLS-associated Tfh cells. TLS and Tfh responses facilitate optimal 
interactions between adaptive and innate immunity, contribute 
to granuloma formation, and improve the quality of T-cell recall 
responses in TB (201). In TB patients, TLS have also been associ-
ated with immune control, but more in-depth research is needed 
to establish their exact functional role and contribution to protec-
tive immunity (201).
Next to TLS formation and function, IL-23 and IL-17 mediate 
the influx of PMN into the lungs and the contribution of these 
cells to protective immunity in TB is increasingly recognized 
(206). Early, but not late PMN recruitment is essential for IL-17-
mediated long-term control of Mtb infection (195) and DCs that 
acquire Mtb through uptake of infected PMN are better able to 
activate T-cells than DCs that directly interact with Mtb them-
selves (203, 222). The ability of IL-17 to induce the production 
of PMN-attracting chemokines in parenchymal cells is markedly 
improved when IL-17 signals in synergy with inflammatory 
mediators such as IL-1β, which again indicates synergy between 
IL-1β and IL-17 responses during acute TB. Prolonged activation 
of IL-1β and IL-17 responses can lead to massive accumulation 
of PMN, and their local necrotic death can also be damaging to 
14
Mourik et al. Interactions between T1-IFNs and Th17 in TB
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 294
the host. However, in the absence of inflammatory stimuli, PMN 
are an important source of IL-10 in the lungs and can initiate 
resolution of inflammation (Figure 4).
4. T1-iFNs, THe Th17 ReSPONSe AND 
THeiR iNTeRACTiONS iN AUTOiMMUNe 
DiSeASe
Autoimmune diseases comprise a wide range of organ-specific 
and systemic disorders. Most systemic AID are considered clas-
sical B cell-mediated diseases, typified by circulating autoreactive 
antibodies against intracellular self-antigens. The clinical presen-
tation of different AID varies, but evidence from genome-wide 
association studies points toward common immunogenetic 
mechanisms, as many systemic AID share disease-associated 
genes (231). Another trait particularly shared amongst different 
antibody-driven AID is the expression of a T1-IFN signature in 
both blood- and disease-affected tissue (232–234), the strength 
of which generally correlates with disease activity and severity 
(235–238). Vice versa, T1-IFN immunotherapy as treatment 
for other diseases is known to cause symptoms similar to those 
observed in AID, such as development of psoriatic lesions in MS 
or hepatitis C-infected patients (239, 240).
T-cells also have a major impact on the development and 
progression of AID and increasing evidence points toward 
crucial involvement of the Th17 response in the pathogenesis 
of multiple AID (160, 241). Th17  cells have been shown to be 
critical in the pathogenesis of MS and rheumatoid arthritis (RA) 
(19, 160). However, Th17  cells have also been associated with 
disease severity in AID characterized by a T1-IFN signature, such 
as systemic lupus erythematosus (SLE) (20, 233, 242, 243). Since 
T1-IFN signatures and Th17 responses are both associated with 
disease in AID, the question arises whether these two pathways 
act in concert to sustain and amplify autoimmune responses, 
or control each other (20, 21, 244). Therefore, we will discuss 
below the involvement of the T1-IFN and Th17 responses in AID 
individually as well as their interaction. We refer readers who are 
familiar with the contributions of T1-IFN and Th17 in AID to 
continue at Section 4.3 where we discuss the interaction between 
these pathways.
4.1. The Contribution of T1-iFNs to the 
Pathogenesis of AiD
Most insight into the role of T1-IFNs in the pathogenesis of AID 
has been obtained in SLE, which was the first disease in which 
a T1-IFN transcriptional signature was identified in 2003 (235). 
Since then it has become clear that 60–80% of adult SLE patients 
and nearly 100% of pediatric SLE patients express a T1-IFN sig-
nature in their blood (245). Several mechanisms through which 
T1-IFNs contribute to disease in SLE, outlined below, have been 
elucidated.
4.1.1. Induction of T1-IFNs in AID
Specifically IFN-α appears to play a central role in SLE pathogen-
esis (245, 246). As mentioned in Section 2.3 IFN-α is produced 
in an IRF7-dependent way by pDC and other myeloid cell types. 
In accordance, pDC have been found to be a major source of 
T1-IFNs in SLE (247, 248). Immune complexes (IC), consisting 
of antibodies bound to self-DNA, are a major trigger for IFN-α 
production by pDC in AID (249). However, pDC are not acti-
vated by self-DNA under steady state conditions, which indicates 
that additional stimuli are required. One such stimulus is the 
PMN-derived antimicrobial peptide LL37 (249), which convert 
inert self-DNA into a potent activator of endosomal TLR9 (250). 
Another stimulus is the nuclear protein high mobility group box 
1 (HMGB1) protein, which is secreted by activated myeloid cells 
and passively released by necrotic, but not apoptotic cells (251). 
HMGB1 binds DNA, and the formed complexes bind with high 
affinity to receptor for advanced glycation end-products, which 
facilitates internalization into the endosome where TLR9 can be 
activated (249). Extracellular HMGB1 also triggers the recruit-
ment of PMN and stimulates their formation of neutrophil 
extracellular traps (NETs) (252). NETs contain large amounts of 
nucleic acids and LL37 and are also a major driving factor behind 
chronic pDC activation and IFN-α production in SLE (253).
It deserves mention that NET formation is driven by reactive 
oxygen species (ROS), which in PMN are particularly produced 
by NADPH oxidase and subsequently processed by myeloper-
oxidase (254). Paradoxically, despite the capacity of NETs to 
induce T1-IFNs and the pathogenic role of T1-IFNs in SLE, 
NADPH oxidase appears to be protective in SLE (255). Lupus-
prone mice deficient in NADPH-oxidase develop more severe 
SLE (255). Moreover, autoimmunity with T1-IFN signatures can 
still develop in individuals with chronic granulomatous disease, 
who lack NADPH-oxidase activity (256). This seeming con-
tradiction has been partially explained by the observation that 
IgG autoantibody-mediated NETosis, which is most relevant in 
SLE, is specifically reliant on mitochondrial ROS, while NETosis 
induced by, e.g., TLR4 signaling is NADPH dependent (256). 
In line with this, NETs from SLE patients have been shown to 
contain mitochondrial DNA (256). Thus, the way NETs are 
induced, and the type of DNA that is present on NETs probably 
also influences their ability to induce T1-IFNs and their role in 
disease.
Taken together, TLR9-mediated IFN-α production by pDC in 
response to IC and NETs appears the major driving factor behind 
T1-IFN production in autoantibody-mediated AID. Additionally, 
the way NETs are induced and the type of DNA present on NETs 
can influence disease outcomes.
4.1.2. Disease-Promoting Effects of T1-IFN in AID
Type I interferons exert a detrimental effect in AID through dif-
ferent pathways. In monocyte-derived cells, T1-IFNs stimulate 
maturation, increase phagocytic capacities (257), and increase 
the expression of co-stimulatory molecules (258). Also, T1-IFNs 
have a direct stimulating effect on T-cells. Together, these effects 
promote the generation of autoreactive T-cells, which support 
autoreactive B-cell responses (257, 259).
At cytokine level, T1-IFNs can induce the production of B-cell 
activating factor (BAFF) by myeloid cells (238, 260, 261). BAFF 
induction confers a significant proportion of T1-IFN-mediated 
damage in SLE as supported by the observation that IFN-α 
administration induces disease in SLE-prone mice but fails to 
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do so in B-cell-deficient and BAFF-deficient mice on the same 
background (262). BAFF plays a central role in the development 
and selection of autoreactive B-cells (260). In line with this, 
increased BAFF expression correlates with disease severity in 
SLE (21, 260, 263). BAFF also induces class switch recombina-
tion in B-cells, leading to preferential expression of IgG and IgA 
over IgM, which is important for Fc-receptor-mediated NETosis 
induction in PMN (264). The clinical relevance of BAFF in SLE 
pathogenesis is illustrated by the current use of belimumab, a 
monoclonal antibody against BAFF, as treatment for SLE (265). 
Interestingly, targeting BAFF is effective in SLE patients, while 
B-cell depleting therapies using CD-20-targeting rituximab show 
disappointing results in phase III clinical trials (266, 267). This 
suggests effector functions of BAFF other than B-cell activation. 
In this regard, BAFF can act as a co-stimulatory molecule for 
T-cells and promote Th17 development (268, 269). BAFF can 
also directly activate plasma cells, which are not depleted by 
rituximab (270, 271).
4.2. The Contribution of Th17 in the 
Pathogenesis of AiD
4.2.1. GM-CSF-Secreting Th17.1 Cells
Pathogenic effects of Th17-mediated immunity in AID have 
been studied most detailed in MS and RA and their respective 
mouse models, experimental autoimmune encephalitis (EAE), 
and collagen-induced arthritis (160, 242). MS was long believed 
to be primarily driven by an IL-12/Th1 response, but this concept 
was challenged by observations in the EAE mouse model for 
MS showing that the IL-23p19 subunit instead of IL-12p35 (see 
Box  3) caused disease (272). In addition, the classic cytokines 
of Th1 and Th17 immunity, i.e., IFN-γ and IL-17, respectively, 
were found dispensable in EAE and instead GM-CSF appeared 
to be the effector cytokine responsible for IL-23-induced 
encephalopathy (118). Notably, while most studies agree on a 
central pathogenic role for GM-CSF in MS, conflicting results are 
reported regarding its cellular source (19, 273–275). One study 
shows that GM-CSF expression in MS patients is promoted by 
the IL-12/T-bet/Th1 axis, instead of IL-23 as observed in mouse 
EAE (273). Other publications report that B-cells are a major 
source of GM-CSF and specifically act in concert with Th17 cells 
(274, 276). In accord with these discrepant results, MS is shown 
to be a heterogeneous disease that can be driven by either Th1 or 
Th17 immunity (242), which also has implications for therapy as 
will be discussed in Section 4.3.1.
One interesting observation in this regard is the development 
of “hybrid” Th17.1 cells that express markers of both Th17 cells 
and Th1 cells. Naïve CD4+ T-cells in both mice and man do not 
express the IL-23 receptor and can either differentiate into T-bet+ 
Th1  cells under influence of IL-12 or differentiate into CCR6+ 
Th17 cells under influence of IL-6 and TGF-β (161). These IL-6/
TGF-β-differentiated Th17 cells have low inflammatory potential 
and are prone to adopt an IL-10-producing regulatory phenotype. 
However, IL-6 also induces STAT3-dependent upregulation of 
IL-23 receptor (277). Subsequent (re)activation of such IL-6-
primed Th17 cells by IL-23 increases Th1-associated T-bet expres-
sion and generates inflammatory IFN-γ/GM-CSF-producing 
Th17.1 cells (161). These cells can also switch their chemokine 
receptor profile and become CCR2+ instead of CCR6+ (161). 
Expression of CCR2 by Th17.1 cells can contribute to their 
inflammatory potential as it can divert their migration to sites 
without concomitant influx of regulatory T-cells, which depend 
on CCR6 for their migration (278).
Mechanistically, it was shown in a mouse EAE model that 
GM-CSF exerted its pathogenic effector function by stimulating 
IL-1β production by monocyte-derived cells (279). This suggests 
a positive inflammatory feedback loop, since IL-1β in turn pro-
motes IL-23 production and development of Th17.1 cells (118). 
A similar pathogenic Th17.1 response is observed in RA, which 
was the first AID in which IL-1β inhibition was approved for 
clinical use (280). Also, regarding the distinction between Th17 
and Th17.1 responses in RA, it should be noted that anti-GM-CSF 
therapy shows more promise than anti-IL-17 in clinical phase I/
II trials (160, 281).
4.2.2. The Contribution of IL-17-Producing Th17 
Cells to AID Pathogenesis
Next to GM-CSF-secreting Th17.1 cells, regular IL-17-producing 
Th17 cells also have been identified as pathogenic in other AID. 
This is best exemplified by the clinical successes of targeting 
IL-17 in psoriasis (282). Th17-associated pathogenic effects in 
SLE also appear to be driven by IL-17 rather than GM-CSF (21, 
283). This is further supported by the specific contribution of 
PMN to disease in SLE, which is dependent on IL-17, opposed to 
GM-CSF that primarily influences the inflammatory potential of 
monocytes in MS and RA.
4.3. interactions between T1-iFNs and the 
Th17 Response in AiD
Systemic lupus erythematosus and other autoantibody-mediated 
AID show a pathogenic role for T1-IFNs, while T-cell-mediated 
AID, such as MS, are driven primarily by GM-CSF-stimulated 
IL-1β production. With the functional dichotomy of IL-1β and 
T1-IFNs in mind, as shown in Figure 2, MS and SLE seem to be 
opposite ends of the disease spectrum in AID instead of dem-
onstrating interactions between T1-IFNs and the Th17 response. 
However, the existence of different Th17 subsets might explain 
this seeming disparity and suggest roles for GM-CSF-producing 
Th17.1 cells in MS and regular IL-17-producing Th17 cells in SLE. 
Both Th17 responses interact differently with T1-IFNs as will be 
discussed here. We identify three relevant interactions: (1) Th17.1 
responses are fueled by T1-IFN-stimulated influx of CCR2+ 
inflammatory monocytes; (2) a pathological IL-17/T1-IFN/BAFF 
axis driven by NET-forming PMN; and (3) Th17 immunity and 
T1-IFNs collaborate in the generation and function of TLS. An 
overview of these pathways is presented in Figure 5.
4.3.1. T1-IFNs Can Contribute to  
Th17.1-Mediated AID
Among MS patients treated with IFN-β, approximately 
30–50% do  not respond favorably to treatment (284). It was 
shown that IFN-β suppresses Th1-mediated inflammation in 
MS but is  ineffective  and may even exacerbate Th17-mediated 
FigURe 5 | interactions between type i interferons (T1-iFNs) and Th17 immunity in autoimmune diseases. The color grading in the figure indicates the 
level of involvement of either Th17 immunity or T1-IFN-associated signaling. (1) T1-IFNs, primarily produced by plasmacytoid dendritic (pDC) but also by 
inflammatory dendritic cells (iDC) and PMN, prime the latter cells toward a T1-IFN/B-cell activating factor (BAFF)-producing phenotype, promote NETosis by PMN 
and stimulate monocyte migration by inducing CCL2 production. (2) BAFF activates B-cells, stimulates tertiary lymphoid structures (TLS) formation together with 
CXCL13, directly promotes Th17 differentiation (not shown), and stimulates the release of IL-1β by iDC. (3) TLS facilitate optimal interaction between activated 
B-cells and antigen-presenting cells (APC), while necrosis, neutrophil extracellular traps, and T1-IFN increase the chance that these APC present self-antigens. 
Subsequent germinal center (GC) reactions within these TLS result in B-cells differentiating into plasma cells that produce large quantities of autoantibodies. These 
autoantibodies can mediate tissue damage and sustain a self-amplifying loop by inducing NETosis through binding the Fc-receptor on PMN. B-cells can also 
contribute to Th17 immunity by their ability to secrete IL-6 and GM-CSF (not shown and uncertain if this is BAFF dependent). (4) NETs trap antibodies. This 
facilitates their Fc-receptor-mediated internalization by pDC in which they stimulate T1-IFN production through endosomal TLR9 activation. Circulating NETs also 
stimulate IL-1β production by iDC and can mediate tissue damage. (5) In a pro-inflammatory feedback loop, IL-23 stimulates the development of GM-CSF-
producing Th17 cells (Th17.1), which in turn, together with BAFF and/or NETs stimulate an inflammatory phenotype in iDC. (6) IL-1β and IL-23 stimulate IL-17 
production by γδ T-cells, while concomitant stimulation with IL-1β and TNF-α is required for IL-17-induced G-CSF and chemokine production in parenchymal cells. 
(7) IL-1β and TNF-α activate PMN to release reactive oxygen species (ROS) and proteases that cause tissue damage. Furthermore, GM-CSF increases longevity of 
PMN (not shown). Finally, the priming of PMN and monocytes prior to entering the site of disease is important for their eventual effector function. For monocytes this 
is shown in more detail in Figure 3.
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inflammation (19). This  is one of the first studies that report a 
detrimental interaction between T1-IFNs and Th17 responses. 
Given the importance of Th17.1 cells in MS, this negative outcome 
might be explained by the observation that IFN-β therapy in MS 
increases CCL2 production (285). Expression of this chemokine 
in the brain recruits inflammatory CCR2+ monocytes as well as 
Th17.1 cells, which switch their chemokine receptor profile from 
CCR6+ to CCR2+ upon terminal differentiation (161). Moreover, 
Th17.1 cells stimulate IL-1β production in CCR2+ monocytes 
(279, 286). Inflammatory monocytes may differentiate locally 
into dendritic cells further stimulating Th17 responses (287). 
Thus, a strongly pro-inflammatory condition is created in Th17.1-
mediated MS. Since regulatory T  lymphocytes rely on CCR6 
rather than CCR2 (279), recruitment of these anti-inflammatory 
cells does not appear to hold pace with the influx of inflammatory 
monocytes and Th17.1 cells in MS.
4.3.2. A Pathological IL-17/T1-IFNs/BAFF Axis in AID
IL-17 induces PMN influx through induction of G-CSF and 
chemokines (see Section 3.4), which contribute to the produc-
tion of IFN-α by pDC via the NETosis process (see Section 4.1.1). 
However, increasing evidence suggests a more prominent 
FigURe 6 | Th17.1 responses in tuberculosis (TB). (1) Type I interferons 
(T1-IFNs) induce CCL2 production in parenchymal cells and MDM, but not 
GMDM. This induces the influx of CCR2+ monocytes that mediate 
detrimental effects in TB as Mtb-permissive cells develop upon T1-IFN 
stimulation. (2) GM-CSF increases IL-1β production, limits responsiveness to 
T1-IFNs, and increases Mtb-killing potential. However, the exact cellular 
source of GM-CSF in TB is unknown. (3) Patients with active TB overexpress 
TGF-β, which may drive Th17 development over Th17.1 in the presence of 
IL-1β and IL-23. Dotted lines implicate mechanisms shown in autoimmune 
diseases that have not been confirmed in TB. Outstanding questions: (1) 
What is (are) the cellular source(s) of T1-IFNs in TB? (2) What is the ratio 
between different Th17 subsets in TB? (3) Do T-cells contribute to GM-CSF 
production in TB?
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contribution of IL-17 and PMN to T1-IFN-mediated disease in 
SLE. First, besides being major inducers of IFN-α production by 
pDC upon NETosis, PMN also appear to be a significant source of 
IFN-α themselves (288, 289). This was related to their sheer num-
bers, as circulating pDC were 27 times more efficient in secreting 
IFN-α, but PMN were 100 times more frequent (289). Second, 
both T1-IFNs and IL-17-induced G-CSF prime PMN for NETosis 
(250, 290). In accord, circulating PMN of SLE patients are also the 
main cells expressing the transcriptional T1-IFN signature and 
release more NETs than PMN from healthy individuals (250, 253, 
288, 289, 291, 292). Thirdly, T1-IFNs stimulate BAFF produc-
tion, which is essential for T1-IFN-mediated pathogenic effects 
in mouse SLE (261, 262, 293). It is recently shown that IL-17 
also induces BAFF production and that IL-17-driven, G-CSF-
dependent PMN recruitment drives plasma cell responses during 
emergency granulopoiesis in a BAFF-dependent way (271). Also, 
therapeutically administered G-CSF, which is physiologically 
induced by IL-17, increases BAFF production by PMN (294).
These interactions indicate a prominent role for IL-17-
mediated PMN influx in T1-IFN-production and induction in 
AID and synergistic induction of BAFF production by IL-17 and 
T1-IFNs. In support of this, IL-17 and Th17 cells are associated 
with disease severity in SLE to similar extent as T1-IFNs (20, 
21, 241, 244). In turn, BAFF can promote Th17 responses (268, 
269). This further suggests an inflammatory loop with a central 
role for PMN in which IL-17, T1-IFNs, and BAFF continuously 
increase each other’s production and contribute to autoantibody-
mediated responses.
4.3.3. T1-IFNs, Th17 Responses, and TLS in AID
Finally, T1-IFNs and Th17 responses converge onto the develop-
ment and functioning of TLS. In these structures, Tfh cells support 
germinal center (GC) reactions in which B-cells differentiate into 
antibody-producing plasma cells and memory cells (295). As 
expected from their function, TLS and Tfh cells are essential com-
ponents in the pathogenesis of multiple autoantibody-mediated 
AID (296–303). The cytokines IL-17 and IL-22 secreted by ILC3, 
γδ T-cells and Th17  cells are required for local TLS formation 
(199, 230, 304). T1-IFN- and IL-17-induced BAFF promote the 
formation and integrity of GCs within TLS and stimulate Tfh 
development (305, 306). T1-IFNs directly induce the expression 
of the Tfh-markers CXCR5 and PD-1 on T cells (307, 308). Also, 
T1-IFNs promote the survival of aberrantly selected B-cells in the 
GC reactions during SLE directly and indirectly through BAFF 
induction as discussed in Section 4.2.2. Thus, it appears that 
by stimulating TLS development, the Th17 response facilitates 
an environment that promotes selection of autoreactive B-cells 
under influence of T1-IFNs and BAFF.
Taken together, several lines of evidence exist for interac-
tions between the Th17 response and T1-IFNs in systemic AID. 
Current data support a scenario in which Th17 immunity fuels 
T1-IFN-related pathology by mediating PMN influx and driving 
TLS formation, which facilitates T1-IFN/BAFF-mediated plasma 
cell responses and autoantibody production. In turn, T1-IFNs 
can support pathogenic Th17.1 responses in AID by driving the 
influx of CCR2+ inflammatory monocytes and potentially CCR2+ 
Th17.1 cells themselves, which locally drive IL-1β mediated 
inflammation. An overview of these interacting pathways is 
shown in Figure 5.
5. iNTeRACTiONS BeTweeN T1-iFNs AND 
Th17 iMMUNiTY iN TB
In the previous section, we have outlined how T1-IFNs and 
Th17 immunity interact in AID (illustrated in Figure 5). These 
interactions primarily concern (1) Th17.1 responses fueled by 
T1-IFN-stimulated influx of CCR2+ monocytes; (2) The IL-17/
T1-IFNs/BAFF axis driven by NET-forming PMN; and (3) syn-
ergism between Th17 immunity and T1-IFNs in TLS formation 
and function. In this section, we assess the relevance of these 
three pathways in TB based on cell types and effector molecules 
involved. Each subsection contains a part of Figure  5, supple-
mented with relevant finding and outstanding questions in TB.
5.1. Th17.1 Responses in TB
Studies in MS and RA emphasize the difference between GM-CSF/
IFN-γ-producing Th17.1 cells and regular IL-17-producing 
Th17  cells. The former primarily increase the inflammatory 
potential of monocytes (Figure  6), while the latter are more 
closely associated with PMN. Data on subtypes of Th17 cells and 
particularly Th17.1 cells in human TB are limited. One study 
shows that circulating GM-CSF+ T-cells are not increased in ATB 
compared to LTBI, but it is unclear if this concerns Th17.1 cells 
or Th1  cells (309). Interestingly, GM-CSF production by both 
granuloma-associated T-cells and circulating CD4+ T-cells in 
TB patients only occurs after mycobacterial antigen stimulation 
(309, 310). In mice, adoptively transferred Mtb-primed Th17 cells 
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FigURe 7 | The iL-17/type i interferons (T1-iFNs)/B-cell activating 
factor (BAFF) axis in tuberculosis (TB). Mtb actively induces NET 
formation by PMN, but subsequent activation of IFN-α production by 
plasmacytoid dendritic (pDC) appears less relevant in TB than in autoimmune 
diseases (AID). IL-17 levels from TB patients vary (Table 3), but preclinical 
models support a protective role. Dotted lines implicate mechanisms present 
in AID that have not been confirmed in TB. Outstanding questions: (1) What 
are the specific contributions of IFN-α vs. IFN-β to disease in the different 
phases of TB? (2) Do BAFF and T1-IFNs promote the observed autoimmune 
phenomena in TB?
that produce IL-17 upon transfer, predominantly produce IFN-
γ upon subsequent contact with Mtb, which is suggestive of a 
Th17.1 phenotype (210).
Th17.1 cells in AID result from prolonged innate IL-1β and 
IL-23 signaling. With regard to the role of IL-1β and IL-23 in 
human TB, IL-1β is essential for the expansion of both IFN-γ−IL-
17+Th17 cells and IFN-γ+IL-17+Th17 cells (311, 312). IL-23 pro-
motes the development of IFN-γ+IL-17+Th17 cells but promotes 
IFN-γ−IL-17+Th17 cells if TGF-β is concomitantly present (312). 
Since active TB is associated with elevated TGF-β levels (178, 313, 
314), it is possible that Th17.1 cell differentiation does not play a 
major role, but this remains to be demonstrated.
Th17.1-derived GM-CSF exerts a pathogenic effect in AID by 
stimulating IL-1β production in CCR2+ monocytes. Although 
the role of Th17.1 cells in TB is uncertain, other cells such 
as NK  cells and Th1  cells can also produce GM-CSF in TB, 
and during the course of infection, GM-CSF levels progres-
sively increase in the lungs of Mtb-infected mice (125, 315). 
The functional role of GM-CSF is of interest in TB, because 
it importantly impacts on CCR2+ monocytes, which play a 
central role in T1-IFN-mediated pathogenic effects. T1-IFNs 
stimulate the influx of inflammatory CCR2+ monocytes but 
inhibit their IL-1β production and stimulate their differen-
tiation into Mtb-permissive cells (see Figure  3). In contrast, 
GM-CSF is protective during acute TB, which is in line with 
the protective effects of IL-1β in this phase of disease. Mice 
deficient in GM-CSF succumb rapidly to infection due to their 
inability to mount Th1 responses (316, 317). Transgenic mice 
that overexpress GM-CSF in the lungs but are GM-CSF-deficient 
in all other organs can develop Th1 responses, but still succumb 
to infection more rapidly than wild-type mice due to their 
inability to develop a normal granulomatous response (316, 
317). Evidence from in  vitro studies suggests that GM-CSF 
exerts its protective effect in TB by countering the effects of 
T1-IFNs in CCR2+ monocytes (36, 94). Under physiological 
conditions, monocytes differentiate under influence of M-CSF 
into monocyte-derived macrophages (MDM). These MDM 
have a CCR2low phenotype, readily produce CCL2 and IL-10 
in response to T1-IFNs, and have a low Mtb-killing capacity 
(94, 156, 318, 319). Conversely, monocytes that differentiate 
under influence of GM-CSF (GMDM) are CCR2high, relatively 
unresponsive to T1-IFN signaling, produce small amounts of 
CCL2 and IL-10, and have better Mtb-killing capacities than 
MDM in response to activation by IFN-γ (36, 126).
The relative unresponsiveness of GMDM to T1-IFNs might 
explain why preclinical studies primarily show effects of T1-IFNs 
during acute TB when the GM-CSF/M-CSF ratio in the lungs 
is relatively low, but less pronounced effects during later stages 
when GM-CSF-levels progressively increase (see Section 2.4.3; 
Figure 3) (125). However, similar to IL-1β, prolonged GM-CSF 
signaling also appears detrimental in TB. In particular, GM-CSF 
contributes to foamy macrophage development during later 
stages of infection, which can sustain persistent mycobacteria 
and contribute to inflammation (125, 320).
In summary, relatively few data are available on Th17.1 cells or 
T-cell-derived GM-CSF in TB. The requirement for antigen stim-
ulation of T-cells to induce expression of GM-CSF is interesting. 
However, elevated TGF-β levels in TB patients suggest a limited 
contribution of Th17.1 cells to disease, as TGF-β favors the devel-
opment of regular IL-17-producing Th17 cells. Regardless of its 
cellular source, preclinical TB studies support a protective role 
for GM-CSF during acute infection. GM-CSF causes monocytes 
to differentiate into cells with decreased T1-IFN responsiveness 
and increased Mtb-killing potential compared to their M-CSF-
differentiated counterparts. However, during chronic Mtb infec-
tion, high GM-CSF levels appear detrimental as they stimulate 
foamy macrophage development and inflammation.
5.2. The iL-17/T1-iFNs/BAFF Axis in TB
In the previous paragraph, it was discussed that regular IL-17-
producing T-cells are more likely to play a role in TB than Th17.1 
cells. Opposed to Th17.1 cells, regular Th17 cells exert their effect 
primarily through PMN instead of CCR2+ monocytes in AID. 
Particularly in SLE, this was shown to be part of a pathogenic axis 
together with T1-IFNs and BAFF. The roles of T1-IFNs and IL-17 
in TB have been discussed already in Sections 2 and 3. In this 
section, we assess the roles of the other components of the IL-17/
T1-IFNs/BAFF axis in TB, which include PMN-derived NETs, 
pDC, and BAFF (Figure 7).
BOx 4 | iFN-α or iFN-β: which is relevant in tuberculosis (TB)?
IFN-α and IFN-β both exert their effect by binding to IFN-α/β receptor, but 
increasing evidence from autoimmune diseases (AID) and viral infections sug-
gests divergent effector functions (328, 329). In AID, this is illustrated by the 
pathogenicity of IFN-α in systemic lupus erythematosus (SLE) opposed to the 
therapeutic application of IFN-β as immunosuppressive treatment in multiple 
sclerosis (MS). Recently, these different immunoregulatory roles of IFN-α and 
IFN-β in SLE and MS have been confirmed by more detailed analysis of blood 
transcriptional profiles in patients (330). The molecular explanation for the 
differential function of IFN-α and IFN-β traces back to subtle differences in 
receptor binding, signaling cascades, and feedback mechanisms initiated and 
has been reviewed in detail elsewhere (28, 331).
The specific contributions of IFN-α and IFN-β to the host response in infec-
tious disease have been studied particularly in mice infected with lymphocytic 
choriomeningitis virus. This work supports an immune-stimulating, antiviral 
role for IFN-α as opposed to an immunosuppressive effect by IFN-β (328, 331, 
332). IFN-β specifically inhibits antiviral T-cell responses and promotes viral 
persistence (331). In contrast, IFN-α-signaling associates with tissue damage 
and antiviral activity (331, 332).
In TB, evidence for the involvement of both type I interferons is present. 
Reactivation of TB has been reported specifically after treatment of patients 
with IFN-α, but not IFN-β (50–57). Also, mice infected with virulent Mtb strains 
specifically show higher IFN-α levels in the lungs compared to less virulent 
strains (64, 65). However, IFN-α-producing plasmacytoid dendritic cells seem 
to be of minor significance in TB patients (325, 327), and preclinical studies 
show that Mtb preferentially induces IFN-β through cytoplasmic pattern 
recognition receptors and IRF3 instead of IFN-α through endosomal toll-like 
receptors and IRF7 (79–81). Mycobacterial persistence in patients with TB 
is a major clinical problem and in line with the immunosuppressed state in 
active TB primarily supports a role for IFN-β (178, 333). However, exaggerated 
innate responses are also observed in TB where IFN-α might be involved. 
This is supported by recent evidence showing that IRF7 drives excessive 
innate inflammation during bacterial infections and provides an interesting 
therapeutic target (334). Taken together, little is known about the separate 
effects of IFN-α and IFN-β in TB, but clinical and preclinical studies support 
a role for both in different disease contexts. The diversification of IFN-α and 
IFN-β responses in transcriptional signatures observed in AID patients and the 
distinct effects of IFN-α and IFN-β in experimental LMCV infection therefore 
provide highly interesting perspectives for TB.
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5.2.1. PMN, NETs, and pDC in TB
PMN isolated from SLE patients are the primary cells that 
express the transcriptional T1-IFN signature. Furthermore, a 
specific subclass of PMN, termed low-density granulocytes 
(LDG) have been identified in SLE that express a pro-
inflammatory phenotype, has increased T1-IFN-production 
and more readily form NETs than PMN from healthy indi-
viduals (291, 292). Similar to SLE, the transcriptional T1-IFN 
signature in TB patients is mostly expressed in PMN (58). 
Moreover, LDG are also present in TB patients and correlate 
with disease severity, but it is unclear if these cells also have a 
similarly increased tendency for NETosis as their SLE counter-
parts (321). Nevertheless, NETosis does occurs in TB, as Mtb 
readily induces NETosis itself in PMN in an ESX-1-dependent 
way and can even stimulate extracellular trap formation in 
macrophages (204, 322–324).
Neutrophil extracellular traps are strong inducers of IFN-α 
production in pDC in SLE (256). Conversely, pDC produce only 
small amounts of IFN-α and appear of minor clinical significance 
in TB (325). In accord, circulating pDC are elevated in SLE (326) 
but reduced in TB patients (327).
Final support for a limited role of pDC in TB pathogenesis 
comes from the observation that pDC produce IFN-α after endo-
somal TLR-activation, while it is shown that Mtb primarily induces 
IFN-β through activation of cytoplasmic PRRs (see Section 2.3) 
(81, 250). While both IFN-α and IFN-β signal through IFNAR, 
this diversification in cellular source and type of T1-IFN that is 
induced can have important consequences for TB pathogenesis 
(see Box 4).
5.2.2. BAFF in TB
Both T1-IFNs and IL-17 can induce BAFF expression, which con-
tributes to disease in SLE as illustrated by the clinical successes of 
BAFF-inhibition (261, 271, 335). BAFF increases B-cell numbers 
and antibody titers (293, 336) and treatment with anti-BAFF in 
SLE patients reduces serum IgG levels (335). The role of BAFF in 
TB has been explored to a much lesser extent, with currently one 
paper demonstrating BAFF levels to be elevated in patients with 
active TB without elaborating on its functional contribution to 
the host response (337).
The functional role of BAFF in TB might be of particular 
interest given its stimulation of humoral immunity and the 
recently demonstrated protective effects of antibody-mediated 
immunity in TB patients (338, 339). Next to antibody-mediated 
protection, B-cells also essentially support T-cell responses in 
TB, but circulating B-cells are dysfunctional and reduced in 
absolute numbers in patients with active TB (340). The protec-
tive effects of Mtb-specific antibodies and B cells in TB suggest 
that increased BAFF levels may supports host responses by 
stimulating antibody production and perhaps other B cell func-
tions such as stimulating T cell responses (338). However, high 
BAFF levels also predispose for the development of autoreactive 
B-cells in AID (341). Thus, elevated BAFF levels in TB could 
relate to the observation that up to 32% of patients with active 
TB have elevated autoantibody levels (12). Such correlations 
between elevated BAFF levels and autoimmunity have been 
demonstrated in other chronic infections (342).
Additional support for a supposed protective role of BAFF in 
TB comes from its interaction with IL-17, which shows protective 
effects in preclinical early infection phase TB models, as discussed 
in Section 3. IL-17 stimulates the migration of PMN to lymphoid 
structures where they can produce large quantities of BAFF that 
directly drive plasma cell responses. Also, IL-17-induced G-CSF 
primes PMN for BAFF production upon activation (271, 294). 
Vice versa, elevated BAFF levels have been reported to increase 
Th17 immunity in AID and infection (268, 269, 343).
Taken together, preliminary pieces of evidence support the 
presence of interactions between IL-17, T1-IFNs, and BAFF in 
TB, similar to those demonstrated in AID. This primarily includes 
the presence of NETs and elevated BAFF levels. However, despite 
the T1-IFN signature observed in TB, NET-induced IFN-α 
production by pDC appears less relevant in TB than in AID, and 
the specific contributions of IFN-α and IFN-β are of high inter-
est in TB, but currently largely unknown. Studies in TB patients 
show protective effects of antibody-mediated immunity but also 
elevated titers of autoantibodies. This supports a view in which 
BAFF is protective in TB, but excessive BAFF levels, driven by 
either T1-IFNs or IL-17 can also increase the chances of develop-
ing autoimmunity in TB patients.
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Another interesting observation regarding Tfh responses 
concerns the induction of PD-L1 expression on APC and PD1 
on T-cells by T1-IFNs (43, 136, 307). In TB circulating PMN pri-
marily express the T1-IFN signature but also overexpress PD-L1 
(58, 347). The interaction of PD-L1 with PD1 on CD4+ T-cells 
is a key immunological checkpoint in TB that limits excessive 
T-helper responses (33, 35). In line with this, PD1-deficient mice 
are extraordinarily susceptible to TB (34). Tfh cells constitutively 
express PD1+, which distinguishes them from conventional CD4+ 
Th cells. Interestingly, while increased PD1/PD-L1 interaction 
suppresses conventional T-helper responses, the opposite is 
observed for Tfh responses (348). Interaction between PD1+ Tfh 
cells with PD-L1 has a stronger suppressive effect on the regula-
tory subset of Tfh cells than on stimulatory Tfh cells and results in 
a net increase of Tfh activity (348).
Taken together, IL-17, T1-IFNs, and BAFF act in concert to 
drive TLS formation and Tfh responses. These responses support 
the development of autoreactive B-cells and the subsequent pro-
duction of autoantibodies in AID but confer protective immunity 
in TB by improving the interaction between adaptive and innate 
cells and facilitating antibody production, while simultaneously 
inhibiting excessive inflammation by conventional CD4+ T-cell 
responses.
6. CONCLUDiNg ReMARKS
The notion that complex mechanisms beyond Th1 immunity 
are at play in TB immunity is supported by (1) the unsatis-
factory results of vaccine strategies aimed at boosting Th1 
immunity in TB patients (31); (2) the inflammatory damage 
associated with increasing IFN-γ production by T-cells in the 
lungs of Mtb-infected mice (33); and (3) the host-detrimental 
effect of targeting the Th1-inhibiting PD1/PD-L1 interaction 
in mice (34, 35).
Patients with active TB express a T1-IFN transcriptional 
signature in their circulating leukocytes, but the exact identity 
and functional role of T1-IFNs in patients remains to be elu-
cidated (62). Others have speculated that deleterious effects 
of T1-IFN-signaling during bacterial infections are tolerated 
because of their ability to suppress myeloid cell responses (41). 
This review highlights two additional aspects of T1-IFNs that 
are of interest in TB. The first concerns the preconditioning of 
myeloid cells prior to their contact with T1-IFNs. IFN-γ prim-
ing appears essential for the induction of an Mtb-permissive 
phenotype, and monocytes that differentiate under GM-CSF 
are less responsive to T1-IFNs than their M-CSF-differentiated 
counterparts (Figure 3) (43, 94). The second aspect is the diver-
sification of IFN-α and IFN-β responses on a transcriptional 
and functional level as explained in Box 4. We propose that the 
inflammatory effects of IRF7-mediated IFN-α might contribute 
to excessive innate inflammatory responses in TB, while the 
immunosuppressive effects of IFN-β are more likely to support 
mycobacterial persistence.
Determination of the role of the Th17 response in TB is 
impeded by its heterogeneity, reflected in the presence of 
different Th17 subsets with ranging inflammatory potentials. 
Observations in AID emphasize the difference between IFN-γ/
FigURe 8 | Tertiary lymphoid structures (TLS) in tuberculosis (TB). 
TLS, Tfh cells, B-cells, and antibodies are all associated with protective 
immunity in TB. Preclinical TB models show that TLS induction and CXCL13 
production are driven by IL-17 and IL-23. Type I interferons (T1-IFNs) and 
B-cell activating factor (BAFF) support TLS function and Tfh responses in 
autoimmune diseases (AID). In TB, T1-IFNs and BAFF are associated with 
active disease, but their functional role remains to be identified. Dotted lines 
implicate mechanisms present in AID that have not been confirmed in TB. 
Outstanding question: (1) What are the functional roles of T1-IFNs and BAFF 
in TLS function and humoral immunity in Mtb infection?
5.3. TLS in TB
As a third place of interaction, IL-17, T1-IFNs, and BAFF converge 
in the local formation and functioning of TLS. In these structures, 
Tfh cells support GC reactions in which B-cells differentiate into 
plasma cells and memory cells (295). As discussed in Section 4.3.4, 
observations in AID suggest that Th17 responses drive TLS devel-
opment and facilitate an environment that promotes development 
of autoreactive B-cells under influence of T1-IFNs and BAFF. 
Conversely, both TLS and Tfh cells are associated with immune 
control in TB patients and preclinical TB models, which is in line 
with the protective role of humoral immunity in TB discussed in 
the previous section (194, 201, 344, 345). Here, we discuss how 
TLS and Tfh responses are associated with protective immunity in 
TB and how interactions between IL-17, T1-IFNs, and BAFF may 
contribute to this immune response.
Migration of CXCR5+ Tfh cells into TLS is largely dependent on 
CXCL13, which is primarily induced by IL-23 and IL-17 in mouse 
TB models but can also be induced by T1-IFNs, as demonstrated 
in viral infections (194, 346). Mechanistically, CXCR5+ Tfh cells 
mediate their protective effect in Mtb-infected mice by facilitat-
ing optimal localization of effector T-cell populations within the 
lung parenchyma, thereby promoting efficient T-cell-dependent 
macrophage activation and intracellular Mtb killing (194, 201).
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